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Abstract
The chemoprotective properties of sulforaphane (SF), derived from cruciferous vegetables,
are widely acknowledged to arise from its potent induction of xenobiotic-metabolizing and
antioxidant enzymes. However, much less is known about the impact of SF on the efficacy
of cancer therapy through the modulation of drug-metabolizing enzymes. To identify pro-
teins modulated by a low concentration of SF, we treated HT29 colon cancer cells with
2.5 μMSF. Protein abundance changes were detected by stable isotope labeling of amino
acids in cell culture. Among 18 proteins found to be significantly up-regulated, aldo-keto
reductase 1C3 (AKR1C3), bioactivating the DNA cross-linking prodrug PR-104A, was fur-
ther characterized. Preconditioning HT29 cells with SF reduced the EC50 of PR-104A 3.6-
fold. The increase in PR-104A cytotoxicity was linked to AKR1C3 abundance and activity,
both induced by SF in a dose-dependent manner. This effect was reproducible in a second
colon cancer cell line, SW620, but not in other colon cancer cell lines where AKR1C3 abun-
dance and activity were absent or barely detectable and could not be induced by SF. Inter-
estingly, SF had no significant influence on PR-104A cytotoxicity in non-cancerous,
immortalized human colonic epithelial cell lines expressing either low or high levels of
AKR1C3. In conclusion, the enhanced response of PR-104A after preconditioning with SF
was apparent only in cancer cells provided that AKR1C3 is expressed, while its expression
in non-cancerous cells did not elicit such a response. Therefore, a subset of cancers may
be susceptible to combined food-derived component and prodrug treatments with no harm
to normal tissues.
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Introduction
Cancer drugs are often associated with severe side effects that limit dosing potential, therefore
prodrugs that require bioactivation in target cells are actively pursued as a strategy to promote
therapeutic selectivity [1]. To further differentiate between target and non-target cells, particu-
larly for enzyme-activated prodrugs, a novel alternative approach is to selectively precondition
cancer cells with non-toxic amounts of a natural bioactive compound to safely enhance drug
susceptibility [2]. These compounds often up-regulate drug metabolizing enzymes that bioacti-
vate drugs, therefore despite low exposures, they may significantly impact therapy outcomes
[3]. Unlike drug-drug interactions, food-modulated changes in drug metabolism that influence
drug efficacy in cancer therapy have rarely been addressed.
Isothiocyanates such as sulforaphane (SF) are derived from cruciferous vegetables, are bio-
available in the colon [4], and modulate gene expression of a large number of xenobiotic-
metabolizing and antioxidant enzymes [4–6]. To a large extent, this process is mediated by the
transcription factor nuclear factor erythroid 2-related factor 2 (Nrf2) [7]. The influence of SF
on gene transcription and protein expression has been characterized in rodent models and
human cell lines from different tissue origin [8–18], including four studies entailing proteomic
approaches [14, 16–18]. SF reacts with cysteine residues of the Nrf2 repressor Keap1, resulting
in nuclear translocation of Nrf2 and binding of the transcription factor to DNA [7]. Gene
expression is affected mainly for genes that code for phase II and detoxification enzymes, but
also cellular NADPH-regenerating enzymes, antioxidants, or xenobiotic-metabolizing enzymes
[14–18]. Most translational applications of SF aim to exploit the regulation potential for deacti-
vating electrophiles and reactive oxygen species in healthy or pre-malignant cells for cancer
prevention [15, 19].
While SF or high levels of Nrf2 may contribute to chemoresistance [7, 20], the opposite rela-
tionship has also been observed, with key differences being mechanism of drug action and cell
characteristics [21]. Most known instances involve a direct therapeutic function of SF in a
drug-like manner, however, there is limited knowledge regarding influences of non-toxic, low
concentrations of SF potentially achieved by the diet. A process of particular relevance is how
transcriptional activation of drug-activating enzymes may promote the action of cancer pro-
drugs. In this regard, it has been observed that when cancer cells (breast TD47D) were treated
with SF, NAD(P)H:quinone oxidoreductase 1 (NQO1), an activator of mitomycin C (MMC),
was induced and cells were sensitized to MMC [22]. In a follow-up study, dimethyl fumarate
was used as NQO1 inducer, and the initial SF findings were confirmed in vivo. Importantly,
there were no observed increases in adverse toxicities, motivating further study of how diet-rel-
evant enzyme induction may impact prodrug activity [23]. These data, together with the estab-
lished bioavailability of SF in the human colon, suggested to us the relevance of characterizing
proteome-wide changes in human colon cancer cells exposed to non-toxic doses of SF using
stable isotope labeling with amino acids in cell culture (SILAC) [24], a metabolic labeling
approach that allows the quantification of thousands of proteins with high precision and sensi-
tivity [25].
PR-104A is the prodrug metabolite of the dinitrobenzamide mustard pre-prodrug PR-104
(Fig 1) [26–29]. In previous studies, the enzyme aldo-keto reductase (AKR) 1C3 has been
established to mediate the aerobic activation of PR-104A [29, 30]. This enzyme is a member of
the AKR enzyme superfamily, comprised of ketosteroid reductase enzymes that regulate the
production of androgens, estrogens, and progestins [31] and its expression is regulated by the
Nrf2/Keap1-pathway [29]. PR-104 has been involved in a number of early clinical trials for
cancer therapy [32–35], however, a potential beneficial effect of chemically induced enzyme
expression on PR-104A cytotoxicity has not been reported.
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To determine the influence of a low SF concentration that might be exploited for the modu-
lation of drug efficacy, we analyzed proteome-wide changes upon SF preconditioning in HT29
colon cancer cells by SILAC [24]. On the basis of these data, we formulated the hypothesis that
PR104A activity may be promoted in cancer cells. Therefore, we tested the impact of SF pre-
conditioning on PR-104A cytotoxicity in these and several other established colon cancer cell
lines and compared to immortalized but normal diploid human colonic epithelial cells
(HCEC) as a model for healthy colon tissue. A range of data from cellular uptake, enzyme
abundance, activity in different cell types and knock-down assays suggest a model involving
SF-promoted sensitization on the basis of increased AKR1C3 protein abundance and activity,
and cellular characteristics that favor the positive interaction.
Materials and Methods
Materials
Cell culture medium and supplements were from Invitrogen (Life Technologies) and chemicals
from Sigma Aldrich, if not otherwise specified. Stock solutions of R-sulforaphane (LKT Laborato-
ries) and PR-104A (Proacta) were prepared in DMSO, chlorambucil in ethanol. NADPH was
from Calbiochem. Coumberone was generously provided by Prof. Dalibor Sames (Columbia
University, NY, USA) and SN34037 by Prof. Bill Wilson and Dr. Adrian Blaser (Auckland Can-
cer Society Research Centre, University of Auckland, New Zealand). ON-TARGETplus Human
AKR1C3 siRNA (SMARTpool) and ON-TARGETplus non-targeting pool siRNA were obtained
fromDharmacon (Thermo Scientific). Lipofectamine RNAiMAX transfection reagent (Life
Technologies) was used for siRNA transfection according to the manufacturer's protocol.
Fig 1. Activation of the bioreductive prodrug PR-104A, a metabolite of the dinitrobenzamidemustard pre-prodrug PR-104, by aromatic nitro-
reduction. In vivo, PR-104 is hydrolyzed to PR-104A, which is further reduced to metabolites that form cytotoxic ICLs.
doi:10.1371/journal.pone.0150219.g001
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Cells and Culture Conditions
HT29 cells were obtained from the Leibnitz-Institut DSMZ GmbH in January 2012. SW620,
SW480, HCT116 and GP2d cells, described in [36, 37], were obtained from the Institute of
Molecular Cancer Research (University of Zurich, Switzerland) in October 2013 and authenti-
cated by the company Microsynth (Balgach, Switzerland) using short tandem repeat profiling
in January 2015. HT29, SW620 and GP2d cells were grown in DMEM, SW480 cells were cul-
tured in RPMI-1640 medium and HCT116 cells were grown in McCoy’s medium. All media
were supplemented with 10% (v/v) fetal bovine serum and 100 units/mL penicillin and 100 μg/
mL streptomycin. HCEC clones were obtained in August 2011 (HCEC1CT) and August 2013
(HCEC2CT) and grown under previously reported conditions, but under normoxia [38]. All
cell lines have regularly been confirmed to be mycoplasma free. For SILAC experiments, HT29
cells were grown in lysine and arginine free DMEM (Silantes) that was either supplemented
with 0.219 mM lysine (Lys0) and 1.14 mM arginine (Arg0) for the light medium (L), while the
heavy medium (H) was supplemented with 0.219 mM [13C6
15N2]-lysine (Lys8) and 1.14 mM
[13C6
15N4]-arginine (Arg10). For a complete incorporation of the isotope-labelled amino acids,
cells were grown for a total of 24 cell population doublings (six passages, 4 cell population dou-
blings each) in SILAC medium prior to the experiment. 24 h after seeding, cells grown in
SILAC light medium were treated with 0.1% (v/v) DMSO and cells grown in SILAC heavy
medium were treated with 2.5 μM SF for 48 h. All cell samples were prepared in triplicates.
Protein Extraction
Cells were trypsinized, washed with PBS, and incubated at 4°C for 15 min with lysis buffer (150
mMNaCl, 50 mM Tris HCl, 1 mM EDTA, pH 7.4) containing protease inhibitors (Complete
Mini, Roche Diagnostics). Lysate was sonicated and centrifuged, protein concentration deter-
mined by BCA assay (Thermo Fisher Scientific), and samples stored at -80°C.
SILAC
Protein digestion, mass spectrometric analysis of SILAC samples and bioinformatics analysis
was performed by adaptation of standard approaches (full details regarding method established
for this study in S1 Appendix).
AKR1C3 Activity
AKR1C substrate coumberone was used as activity probe together with a specific AKR1C3
inhibitor (SN34037) by modification of the method described in [30]. In 96-well plates for each
sample, 40 μg of total protein were added to assay buffer (100 mM KPO4 buffer [pH 7] con-
taining 250 μMNADPH) with or without 1 μM SN34037, and incubated 60 min, 37°C. The
reaction was initiated with coumberone (30 μM final; DMSO 5% [v/v]). Fluorescence emission,
due to the formation of coumberol, at 510 nm (385 nm excitation) was recorded on an infinite
M200 PRO plate reader (Tecan) at 37°C. AKR1C3 activity was calculated as ΔRFU/min over
60 min (full coumberone metabolism in S1 Fig). Measurements performed in duplicate with
biological triplicates; statistical analysis (mean values, student’s t-test) performed using Graph-
Pad Prism 6.
Western Blot Analysis
Cell lysates were separated on NuPAGE1 4–12% Bis-Tris gel at 200 V for 45 min in 1X
NuPAGE1MES SDS running buffer (Life Technologies) and electrophoretically transferred
to Amersham Hybond-P PVDF membrane (GE Healthcare) at 30 V for 60 min in 1X
SF Preconditioning Sensitizes Cancer Cells
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NuPAGE1 transfer buffer (Life Technologies). PVDF membranes were blocked with 5%-
milk-TBST at RT. The membranes were incubated with rabbit polyclonal anti-AKR1C3 anti-
body (1:2’000, Thermo Scientific), followed by incubation with anti-rabbit IgG HRP antibody
(1:5’000, GE Healthcare). The protein was detected using a Pierce1 ECLWestern Blotting
Substrate (Thermo Scientific). Treated membranes were exposed to X-ray film. The membrane
was stripped, incubated with anti-actin antibody (1:1'000, Sigma Aldrich) and analyzed again.
Protein bands were quantified with ImageJ software [39], and were adjusted for corresponding
actin loading control.
Drug Cytotoxicity
Cells were seeded in 96-well plates (HT29, HCEC, SW480: 1’500 cells/well; SW620: 1'000 cells/well;
HCT116: 500 cells/well; GP2d: 5'000 cells/well). 24 h later cells were exposed to 2.5 μMSF (excep-
tion HCT116: 1 μM) corresponding to an IC10 or 0.1% (v/v) DMSO. After 48 h, medium was
removed and increasing concentrations of drug in fresh medium were added. 24 h afterwards
medium was replaced by fresh medium. 72 h later cell viability was assayed using the CellTiter-
Glo1 Luminescent Cell Viability Assay (Promega) according to the manufacturer’s protocol. The
experiment was performed in triplicate. All luminescence values were normalized relative to vehi-
cle-treated cells. The dose-response curves were fitted by a nonlinear regression function in Graph-
Pad Prism 6. Statistical analysis was performed by extra sum-of-squares F test to test if dose-
response curves in control and SF-pretreated cells statistically differ from each other.
PR-104A Cytotoxicity with siAKR1C3
HT29 cells were seeded in 6-well plates (90’000 cells/well) and allowed to attach. 24 h later they
were exposed to siAKR1C3 (120 pmol) and 2.5 μM SF or 0.1% DMSO simultaneously. After 48
h, medium was removed and three concentrations of PR-104A (0, 25, 100 μM) were added in
fresh medium. 4 h after adding the drug, the medium was removed and a clonogenic survival
assay was performed according to standard protocols [40]. After two weeks incubating, colo-
nies were stained with Giemsa stain and counted. As a control, non-targeting siRNA (120
pmol) was used. The experiment was performed in triplicate. Statistical analyses (unpaired t-
test with Welch’s correction) were performed using GraphPad Prism 6.
SF Uptake
Intracellular SF concentrations in HT29 and HCEC1CT cells were measured by the HPLC-
coupled cyclocondensation assay (reaction with 1,2-benzenedithiol), as previously described
(further details in S1 Appendix) [41].
Results
Influence of SF on gene expression in HT29 colon cancer cells
SILAC was used to investigate changes in abundance levels of cellular proteins upon treatment
with a low concentration of SF in HT29 colon cancer cells. After treatment with 2.5 μM SF for
48 h, corresponding to an IC10 in HT29 cells (S2 Fig); we identified 23 differentially abundant
proteins (Fig 2; Table 1). A preponderance of proteins involved in cellular metabolic and redox
processes were found to be enriched, and enzymes characterized previously to mediate the acti-
vation of reductive prodrugs, such as AKR1C3, PTGR1, and NQO1 were amongst this group
[22, 29, 42–44]. The largest fold change was evident for Cyclin-D1-binding protein 1, a nega-
tive regulator of transcriptional activation involving the E2F transcription factors [45], whereas
several metabolic and redox-regulating proteins regulated by the transcription factor Nrf2,
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including AKRs and an aldehyde dehydrogenase, increased by 4.6-fold or higher. The large
change in abundance for AKR1C3 (7-fold), previously implicated in the activation of PR-
104A, invoked the possibility for drug sensitization. Therefore, we focused our further efforts
in elucidating any SF-PR104A interactions and contributions of AKR1C3 as a molecular basis.
A full list of all quantified proteins in the SILAC experiment, including their normalized H/L
ratio, is provided in S1 Table.
To independently confirm the increase in AKR1C3 abundance apparent in the SILAC study,
Western Blot analysis was performed and it was found that AKR1C3 abundance was induced in
HT29 cells in an SF dose-dependent manner (Fig 3A). To confirm higher AKR1C3 activity in
HT29 lysates, we used a modified version of a method previously described for measuring specifi-
cally AKR1C3 activity in intact cells, involving coumberone as a substrate for all four members of
the AKR1C family, and the specific AKR1C3 inhibitor SN34037 [30]. Similar to protein levels,
AKR1C3 activity increased in a dose-dependent manner in HT29 cells (Fig 3A).
Impact of SF-mediated AKR1C3 induction on drug toxicity in HT29 colon
cancer cells
We found that by preconditioning HT29 cells with 2.5 μM SF for 48 h, followed by treatment
with increasing doses of PR-104A, a significant 3.6-fold decrease in the EC50 of the drug was
Fig 2. Volcano plot showing significant changes in the proteome following exposure of HT29 cells to
2.5 μMSF for 48 h, determined by SILAC. 2653 proteins (black and gray) were quantified and tested for
significance. Among the 23 significantly regulated proteins (black), 18 were up-regulated and 5 down-
regulated in abundance.
doi:10.1371/journal.pone.0150219.g002
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observed (Fig 3B; Table 2; p< 0.0001). Higher SF concentrations were tested for the precondi-
tioning, but increasing toxicity of the pretreatment itself prevented the further use of these
higher SF concentrations. As a control, this interaction was compared with the influence of SF
preconditioning on the cytotoxicity of chlorambucil (CBL), an anticancer drug that also forms
DNA interstrand cross-links (ICLs) but does not rely on enzymatic bioactivation. As expected,
the cytotoxicity of CBL was unchanged (Table 2).
To confirm if increased AKR1C3 abundance levels due to SF preconditioning of HT29 are
responsible for the increased cytotoxicity of PR-104A, we performed RNA interference using a
pool of four siRNAs against AKR1C3. A clonogenic assay was used to determine cytotoxicity of
PR-104A in HT29 cells after simultaneous preconditioning with SF and siRNA against
AKR1C3 (Fig 3C and 3D, S2 Table). As control, non-targeting siRNA was used. Furthermore,
varying incubation times and siRNA concentrations were tested to ensure that the SF-induced
AKR1C3 expression was repressed by the siRNA against AKR1C3 under the conditions
described, and after 48 hours simultaneous preconditioning with SF and siRNA against
AKR1C3, protein levels were similar to levels in untreated HT29 cells (data not shown). When
the SF-induced AKR1C3 overexpression was down-regulated via RNA interference, the cyto-
toxicity of PR-104A was reduced, indicating that SF preconditioning lowered the PR-104A
concentration required to achieve a similar cytotoxicity by inducing AKR1C3 abundance
Table 1. Fold changes in protein abundance for SF-treated HT29 cells compared to untreated counterparts.a
Protein Name Gene Name Fold Change Protein Abundance (SF/Vehicle)b
Cyclin-D1-binding protein 1 CCDB1 9.8
Aldo-keto reductase family 1 member C3c AKR1C3 7.3
Aldo-keto reductase family 1 member B10c AKR1B10 5.8
Aldehyde dehydrogenase, dimeric NADP-preferring ALDH3A1 4.6
Glutamate-cysteine ligase catalytic subunit GCLC 3.0
Sulﬁredoxin-1 (EC 1.8.98.2) SRXN1 2.9
Glutamate-cysteine ligase regulatory subunit GCLM 2.8
Glucose-6-phosphate 1-dehydrogenase G6PD 2.3
Prostaglandin reductase 1 PTGR1 2.2
UDP-glucose 6-dehydrogenase UGDH 2.2
NAD(P)H dehydrogenase (quinone) 1 NQO1 2.0
Transketolasec TKT 2.0
Thioredoxin reductase 1 TXNRD1 2.0
Fatty aldehyde dehydrogenase ALDH3A2 1.9
Phosphoserine aminotransferase PSAT1 1.8
Thioredoxin TXN 1.6
6-phosphogluconate dehydrogenase PGD 1.6
Glutathione Reductase, mitochondrial GSR 1.6
Villin-1 VIL1 0.7
Beta-2-microglobulin B2M 0.6
Creatine kinase B-type CKB 0.6
Selenoprotein O SELO 0.6
Tubulin polymerization-promoting protein family member 3 (TPPP/p20) TPPP3 0.5
a. Incubating HT29 cells for 48 h with 2.5 μM SF twenty-three proteins were found to be signiﬁcantly modulated (n = 3; p-value < 0.1, fold change < 0.67
or > 1.5).
b. Ratio H/L normalized
c. Proteins reported as non-differentiable protein groups.
doi:10.1371/journal.pone.0150219.t001
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levels. These data support the previously established link between AKR1C3 abundance and
PR-104A efficacy [29, 30], and furthermore confirms the same effect under conditions of
chemical induction, i.e. with SF.
Impact of SF preconditioning on drug toxicity in HCEC non-cancerous
colonic cells
Promoting drug cytotoxicity in cancer tissue may be beneficial if the same interaction is absent
or reduced in healthy counterparts. Therefore, the combination of SF and PR-104A was inves-
tigated in an immortalized human colonic epithelial cell line (HCEC) as a model for non-
cancerous tissue [38]. HCECs (HCEC1CT and HCEC2CT, from two different individuals) are
non-tumorigenic diploid cells that express epithelial as well as stem cell markers and were
established from normal colonic mucosa. They do not carry mutations in hot spot genes such
as APC, KRAS, or TP53 [38]. AKR1C3 abundance levels measured by Western Blot were
slightly induced upon SF treatment in HCEC1CT cells (Fig 3E), but to a lower extent than for
Fig 3. Influence of SF on AKR1C3 activity, protein expression, and PR-104A cytotoxicity. AKR1C3 activity and protein levels are shown in (a) for HT29
cells and in (e) for HCEC1CT cells treated 48 h with SF or DMSO (control). Bars represent mean values and error bars are standard errors. Statistical
analysis was performed by an unpaired t-test with Welch’s correction. Experiments were performed in triplicate. (*: p < 0.05; RFU = relative fluorescence
units). Modulation of cell viability is shown for HT29 in (b) and for HCEC1CT in (f) after cells were incubated 48 h with 2.5 μMSF or 0.1% DMSO (control) and
incubated with increasing concentrations of PR-104A. Data shown are mean values ± SD from four (HT29) or three (HCEC1CT) biological replicates. An
extra sum-of-squares F test was performed to test whether dose-response curves statistically differ from each other. The resulting p-values show that SF
significantly impacts drug response in HT29 cells, and has no significant effect in HCEC1CT cells. (c) Clonogenic survival assay showing increased survival
of HT29 treated with siRNA against AKR1C3 compared to cells treated with non-targeting siRNA after PR-104A treatment for 4 h. Cells were pretreated for
48 h with 2.5 μMSF together with siRNA. Each data point represents three independent experiments. Error bars show SD of the mean. Statistical analysis
was performed by an unpaired t-test with Welch’s correction; **: p < 0.01, ***: p < 0.001. (d) Western Blot showing levels of AKR1C3 protein in HT29 cells
treated with either non-targeting siRNA or siAKR1C3 with or without simultaneous SF treatment (control = 0.1% DMSO).
doi:10.1371/journal.pone.0150219.g003
Table 2. PR-104A and CBL cytotoxicity in colon cell lines pretreated with SF.a
HCEC1CT HCEC2CT HT29 SW620 SW480 HCT116 GP2d
PR-104A EC50 (μM) control
b 160.1 82.5 48.0 23.3 129.4 104.2 84.8
95% conﬁdence interval 128.8–198.9 66.3–102.8 34.4–67.1 18.0–30.1 109.1–153.4 81.8–133.0 44.2–162.6
PR-104A EC50 (μM) SF pretreated
b 138.3 92.3 13.3 6.4 103.7 70.3 84.2
95% conﬁdence interval 105.7–180.8 73.0–116.7 9.8–17.9 4.7–8.6 84.1–127.8 51.0–96.8 50.2–141.1
p-valuec 0.2 0.8 <0.0001 <0.0001 0.3 0.2 1.0
CBL EC50 (μM) control
b 77.7 30.7 49.3 36.9 41.3 26.2 23.2
95% conﬁdence interval 56.7–106.5 22.7–41.6 32.6–74.7 20.8–65.7 33.4–51.1 21.2–32.5 14.4–37.5
CBL EC50 (μM) SF pretreated
b 66.7 40.7 42.8 24.6 32.0 27.2 22.4
95% conﬁdence interval 42.6–104.3 28.6–58.1 24.3–75.3 16.4–36.9 21.8–47.0 21.7–34.0 14.6–34.4
p-valuec 0.7 0.5 0.9 0.5 0.1 0.9 1.0
Tissue origin normal normal cancer cancer cancer cancer cancer
Basal mRNA AKR1C3d ndf ndf 11.3 11.3 4.2 5.0 9.1
AKR1C3 activity control (ΔRFU/min)e 10.6 116.4 96.6 217.1 -23.6 5.9 28.0
AKR1C3 activity SF pretreated (ΔRFU/min)e 25.9 185.0 417.1 375.3 8.1 6.2 178.1
a. Cells were pretreated with either 0.1% DMSO (control) or 2.5 μM SF (exception: HCT116: 1 μM).
b. Corresponding 95% conﬁdence intervals are shown below the EC50 values.
c. Extra sum-of-squares F test to test if dose-response curves in control and SF pretreated cell statistically differ from each other.
d. Basal mRNA level (log2) as assessed in [51], using Affymetrix U133 plus 2.0 arrays.
e. ΔRFU/min. Corresponding data shown in Fig 4A.
f. nd = not determined
doi:10.1371/journal.pone.0150219.t002
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the HT29 cells (Fig 3A). There was neither significant increase in AKR1C3 activity (Fig 3E) nor
drug susceptibility (HCEC1CT: Fig 3F; Table 2; p = 0.2; HCEC2CT: Table 2; p = 0.8).
SF uptake in HT29 and HCEC1CT cells
To examine whether the different response in HT29 vs. HCEC1CT cells might be related to cel-
lular SF uptake, we analyzed SF uptake in HT29 and HCEC1CT by a cyclocondensation assay.
This assay has the advantage of allowing quantification of free SF as well as SF bound to cellular
thiols such as glutathione [41]. There were no significant differences in SF uptake (S3 Fig), sug-
gesting the exclusion of increased uptake as a basis for the SF-PR104A interaction in HT29 but
not HCEC cells.
Impact of SF preconditioning on drug toxicity in additional colon cancer
cell lines
To explore the generality and basis of SF preconditioning effects, cytotoxicity experiments
were performed with additional colon cancer cell lines with different genetic backgrounds
(Table 2). Similar to HT29, in SW620 the EC50 of PR-104A was significantly reduced 3.6-fold
by SF preconditioning (p< 0.0001). As in HT29 cells, AKR1C3 abundance in SW620 cells was
induced around 3-fold and activity increased 1.7-fold (Fig 4, S3 Table). In contrast, for
HCT116, SW480, and GP2d cells, PR-104A cytotoxicity was not altered. This observation
seems consistent with the fact that no AKR1C3 protein was detected in HCT116 and SW480
cell lysates, and nor did SF preconditioning induce protein abundance or activity (Fig 4, S3
Table). In GP2d cells, AKR1C3 was barely expressed; however, abundance and activity of this
enzyme were not increased sufficiently by SF to alter PR-104A cytotoxicity (Fig 4, S3 Table). A
clear trend was observed towards lower PR-104A EC50 values for cells with higher AKR1C3
activity (Fig 4C, R2 = 0.7063; p< 0.01). These results indicate that a combination of AKR1C3
basal levels and activity, as well as susceptibility to induction by SF, influence the propensity of
cells to support the PR-104A-enhancing potential of SF. Therefore, genetic variation across pri-
mary healthy and tumor tissue, as well as different cancers, may be expected to contribute to
individual responses.
Discussion
Despite the availability of data concerning the impact of SF on gene expression, there was only
limited information available concerning protein abundance alteration in human colon cells,
especially for SF concentrations too low to significantly alter cell viability. In the proteomic
screen conducted here, 23 proteins were differentially abundant, 18 being increased in abun-
dance upon treatment with 2.5 μM SF. Several of these proteins, including different AKRs,
were found previously to be induced by higher doses of SF (5 and 15 μM) in breast cell lines
established from mammary glands with fibrocystic disease and human colon adenocarcinoma
Caco-2 cells also by using proteomic approaches [14, 16]. However, in the present study, the
cellular response was analyzed at a demonstrated non-toxic and potentially physiologically rel-
evant concentration of SF exposure in human tissues (2.5 μM) [46]. At high doses, SF has cyto-
static and cytotoxic activity on cultured cells [47–50]. A moderate change in AKR1C3
abundance (7.3-fold) and generally limited list of up-regulated enzymes detected in our study
may be related to cell type or the low SF concentration, supporting an increase in a high pro-
portion of reductase enzymes even at low concentration.
On the basis of the SILAC results, we explored the potential for SF preconditioning of HT29
cells to alter the cytotoxicity of the bioreductive prodrug PR-104A, and found there to be a pos-
itive interaction directly related to modulation of AKR1C3. Western blot analysis, specific
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enzyme activity measurements, and siRNA knock-down experiments all corroborated that
enhanced sensitivity to PR-104A was related to an increase in AKR1C3 abundance levels and
activity. In contrast, this sensitization was not detectable in immortalized HCEC1CT cells,
Fig 4. AKR1C3 enzyme activity and protein levels in different colon cell lines and correlation between
AKR1C3 activity and PR-104A cytotoxicity. (a) AKR1C3 activity with (gray) and without (black) SF
preconditioning for colon cell lines used in this study. Statistical analysis was performed by unpaired t-test
with Welch’s correction; *: p < 0.05. (b) Western Blot for AKR1C3 protein with and without SF preconditioning
(2.5 μM for 48 h). (c) Correlation between AKR1C3 activity and PR-104A cytotoxicity (p < 0.01). Graph
includes data from HCEC1CT, HCEC2CT, HT29, SW620, and GP2d cells with (open symbols) and without
(closed symbols) SF preconditioning. Cell lines with no AKR1C3 protein (HCT116, SW480) have been
removed. *: significant shift in EC50 upon SF preconditioning according to extra sum-of-squares F test to test
if dose-response curves in control and SF pretreated cell statistically differ from each other.
doi:10.1371/journal.pone.0150219.g004
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consistent with the lack of induced enzyme activity detected in these cells (Fig 4A). On the
basis of western blot data, there appeared to be a relative increase in protein abundance (Fig
4B). However absolute protein levels remained so low in both pre-conditioned and untreated
cells that no effective sensitization was observed. The result for the HCEC1CT cell line was of
interest due to its non-cancer tissue origin and molecular characteristics suggesting it as a
model for healthy colon epithelial cells [38].
The possible selective enhancement of PR-104A in tumor cells motivated us to examine five
additional cell lines, namely HCEC2CT (non-cancerous), and colon cancer cell lines SW480,
SW620, HCT116, and GP2d to better understand how molecular factors influence the combi-
nation response. Similar to HT29, SW620 cells were sensitized towards the treatment with PR-
104A by the SF-pretreatment. Furthermore, AKR1C3 protein abundance and activity was like-
wise induced in these cells. In contrast, protein abundance and activity was not affected by SF-
pretreatment in non-cancerous HCEC2CT cells, therefore these cells were not sensitized
towards the drug. In cell lines that had very low or no AKR1C3 mRNA levels [51] and did not
express the protein (SW480, HCT116), AKR1C3 abundance was also not inducible with SF
preconditioning. Therefore, there was no impact on PR-104A cytotoxicity. GP2d cells had low
AKR1C3mRNA levels [51], but protein abundance and enzyme activity could be increased
upon SF preconditioning, yet with a level of induction seemingly insufficient to impact the
cytotoxicity of PR-104A. Thus, AKR1C3 activity appeared to be more diagnostic of PR-104A
cytotoxicity (Fig 4C) than small protein abundance changes that could be detected by western
blot but were insufficient to have a real effect. This observation lends additional support in the
context of colon cancer cells to the suggestion that AKR1C3 activity could be used as a predic-
tive marker for PR-104A susceptibility as put forth previously on the basis of data from
patient-derived xenografts and leukemia cells. Finally, it suggests a value for continued devel-
opment of strategies to monitor AKR1C3 activity, including activity-based protein profiling
[30, 52, 53].
It has been speculated that additional factors, such as DNA repair, may account for incon-
sistent results observed previously concerning the relationship between PR-104A susceptibility
and AKR1C3 activity in cell lines, however, our data suggest a weak role if any for repair differ-
ences to be significant in the colon cancer cells considering to results obtained with CBL
(Table 2). PR-104A forms ICLs, proposed to be similar to those described for CBL and MMC
[26–28, 54]. When we tested CBL as a model crosslinking agent and analyzed cytotoxicity in
the same cell lines as PR-104A, there was no significant influence of SF preconditioning on cell
viability (Table 2). However, under aerobic conditions, as employed here, PR-104A ICLs are
thought to be only formed if AKR1C3 is expressed, otherwise other modes of action in cell
lines lacking this enzyme have been suggested, such as monoalkylation of DNA by PR-104A
itself or its oxidized half mustard [27, 28, 54]. The structures for such DNA adducts have not
been rigorously characterized, nor their corresponding mode of repair known, therefore the
importance of these pathways in influencing cytotoxicity in cells with low basal or induced
AKR1C3 levels warrants further study.
The possibility of enhancing the cytotoxicity of bioreductive anticancer prodrugs with die-
tary phytochemicals has been demonstrated in a handful of previous studies of human cell
lines [21, 22, 43, 55]. Four cell lines, of colon, lung or breast origin, were sensitized towards the
bioreductive drug MMC by induction of NQO1 [22]. Yu et al. used curcumin and resveratrol
to induce the drug-metabolizing enzyme PTGR1 and therefore sensitize liver HepG2 and
colon SW620 cells towards the bioreductive drug hydroxymethylacylfulvene [43]. A similar
sensitization towards hydroxymethylacylfulvene was obtained in HT29 cells by using D3T as
enzyme inducer [55]. Additionally, there are some in vivo data available, for example, dietary
fish oil increased NQO1 levels in human breast carcinoma tumor xenografts in mice and
SF Preconditioning Sensitizes Cancer Cells
PLOS ONE | DOI:10.1371/journal.pone.0150219 March 7, 2016 12 / 17
increased the MMC sensitivity of these tumors [56]. Human colon tumors (implanted
HCT116 cells) were sensitized towards MMC by feeding mice the NQO1 inducer dimethyl
fumarate [23]. To our knowledge, the effect of SF on the efficacy of bioreductive anticancer
prodrugs, especially PR-104, has not been investigated previously. SF is bioavailable in the
colon [4] and eating cruciferous plants seems to have a high margin of safety [57], suggesting
the combination of SF with PR-104 may promote efficacy. Further studies to evaluate the
robustness and selectivity of the response in vivo are warranted, but not trivial in a model
organism because biotransformation of PR-104 has been shown to differ in humans vs.
rodents, consistent with rodents not expressing a homolog of AKR1C3 [58].
In this study, preconditioning HT29 colon cancer cells with a low concentration of SF led to
selective protein abundance changes within a small number of proteins. A specific cellular pro-
tein abundance and enzymatic activity increase for the reductase enzyme AKR1C3 was of par-
ticular interest as it had a direct positive effect on the cytotoxicity of the nitrogen mustard
bioreductive prodrug PR-104A, but not in immortalized non-cancerous human colonic epithe-
lial cells. In addition to AKR1C3-mediated drug activation, cellular factors differing amongst
colon cell types appears to influence the efficiency of SF-promoted enzyme induction and drug
sensitization, suggesting potential individual differences in responsiveness that may be detected
by biomonitoring AKR1C3 expression or function, or by future identification of additional bio-
markers of responsiveness. The data indicate that dietary bioactive food components such as
SF, even at physiologically feasible concentrations, should be considered for their potential to
alter and possibly benefit bioreductive cancer drug activity.
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